What happened
Damora Therapeutics, Inc. (NASDAQ: DMRA) said Jennifer Jarrett bought 12,500 ordinary shares on 2026-09-25. Jarrett is the company’s director, president and CEO. The Form 4 says the shares were bought at a weighted average price of $20.23 each, for about $252,875. The filing was signed on 2026-09-28.
The shares were bought on the open market with personal funds. The footnote says the purchases were made in several trades at prices from $20.10 to $20.40. It also says full details for each price can be provided on request. After the purchase, Jarrett reported 512,500 shares beneficially owned, including 500,000 RSUs previously granted. The filing does not say whether it was made under a Rule 10b5-1 plan. The trades were spread across several prices.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares acquired | 12,500 shares | SEC Form 4 | |
| Weighted average price | $20.23 per share | SEC Form 4 | |
| Total purchase value | about $252,875 | SEC Form 4 | |
| Shares beneficially owned after the trade | 512,500 shares | SEC Form 4 |
Why it matters
The limit is that this is still one open-market purchase. The reported 512,500-share holding includes 500,000 RSUs previously granted. So the total ownership figure does not mean all of it was bought with cash. For investors, the filing is a current ownership snapshot, not an update on operations. It still gives investors a clean view of the insider's current position. That helps readers see the size of the insider commitment more clearly right away.
What's next
The filing sets a new ownership baseline as of 2026-09-25. The next quarterly report will be the clearest scheduled check. Investors will also watch later insider filings to see whether the stake rises again or stays flat. That makes the next few filings important to track.
For a company whose case depends on turning balance-sheet optionality into validated assets before burn or dilution erodes that value, later operating progress would help. Faster cash use or more dilution would cut against that view. This filing is a baseline, not a verdict. Investors will look for more detail from the company’s operating reports, not just insider forms. If results improve, the ownership update will matter more.
Sources
- SEC Form 4 — Form 4 reporting Jennifer Jarrett's 2026-09-25 open-market purchase and post-trade holdings.
Read the full OptimistFi thesis on Damora Therapeutics, Inc.: https://optimistfi.com/stocks/DMRA
See what would break the Damora Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Damora Therapeutics, Inc. investment case, its status and the next test to watch live on the Damora Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
